Abstract
Despite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer remains the leading cause of death from gynecologic cancer. In the last decade, there have been important advances both in systemic and surgical treatment. However, there is no doubt that the incorporation of PARP inhibitors as maintenance after the response to platinum-based chemotherapy, first in recurrent disease and recently also in first line, will change the natural history of the disease.The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of ovarian cancer, and to provide evidence-based recommendations for clinical practice.
Keywords:
Diagnosis; Guideline; Ovarian cancer; Treatment.
MeSH terms
-
Antineoplastic Agents, Immunological / therapeutic use
-
Bevacizumab / therapeutic use
-
Carcinoma, Ovarian Epithelial / diagnosis*
-
Carcinoma, Ovarian Epithelial / pathology
-
Carcinoma, Ovarian Epithelial / therapy*
-
Chemotherapy, Adjuvant / methods
-
Clinical Trials, Phase III as Topic
-
Cytoreduction Surgical Procedures / methods
-
Female
-
Humans
-
Maintenance Chemotherapy / methods
-
Medical Oncology
-
Neoplasm Recurrence, Local / drug therapy
-
Neoplasm Recurrence, Local / surgery
-
Neoplasm Staging / methods
-
Ovarian Neoplasms / diagnosis*
-
Ovarian Neoplasms / pathology
-
Ovarian Neoplasms / therapy*
-
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
-
Randomized Controlled Trials as Topic
-
Societies, Medical
-
Spain
Substances
-
Antineoplastic Agents, Immunological
-
Poly(ADP-ribose) Polymerase Inhibitors
-
Bevacizumab